Astellas Provides Update On FDA's Decision On Citizen Petition
FDA denies petition for safe and effective use of oral immunosuppressants
Astellas has received the notice that FDA has substantially denied the company’s Citizen Petition, which had been submitted on September 2007, to ensure the safe and effective use of oral immunosuppressants used in organ transplant patients on 10 August, 2009.
Reportedly, in response to that, Astellas has filed a complaint in the US District Court in Washington, DC challenging FDA’s decision. The company requested the court to issue a Preliminary Injunction and Temporary Restraining Order, enjoining FDA’s approval of ANDA for oral immunosuppressant on 11 August, 2009.
Astella is a US affiliate of Tokyo-based Astellas Pharma. In the US, Astellas markets products in the areas of Immunology, Urology, Anti-Infectives, Cardiovascular and Dermatology.
Related Insight
Suppliers Directory
AqVida Oncology - High Barrier to Entry Oncology Generics and Biosimilars
The main focus of AqVida Oncology lies with the development and manufacturing of innovative products, particularly high barrier to entry oncology generics and biosimilars.
Suppliers
InnoCore Technologies BV – Injectable and Implantable Drug Delivery Products and Drug-Eluting Medical Devices
InnoCore is a drug delivery company providing controlled release systems for the pharmaceutical and medical device industry.
Suppliers
SCHOTT Pharmaceutical Systems - Glass Tubing and Primary Packaging for the Pharmaceutical Industry
SCHOTT Pharmaceutical Systems is one of the world's leading suppliers of glass tubing and primary packaging for the pharmaceutical industry. We provide our customers with quality solutions while meeting their highest demands with our material expertise, specialised analytical lab services, and a broad product portfolio made of glass and COC polymer.
Suppliers
The Slimming Solution that Delivers Fat Profits
We are set to launch world-wide a revolutionary new slimming product that is destined to dominate in a multi-billion dollar industry.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Product Brochure
Published by Farfield Group
White Papers
In With the ‘New’: A Leaner, Fitter Biosciences Sector – 2010
Published by Kinapse
White Papers
Reduced Solvent Consumption and Operational Costs with Ultra High Speed Analysis
Published by Shimadzu PBR
White Papers
Phenom™ G2 pure
Published by Phenom World
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.